Borna disease virus and schizophrenia

Royce W. Waltrip, Robert W. Buchanan, Ann Summerfelt, Alan Breier, William T. Carpenter, Nancy L. Bryant, Steven A. Rubin, Kathryn M. Carbone

Research output: Contribution to journalArticle

107 Citations (Scopus)

Abstract

The development of a new serological assay method to detect antibodies in human sera recognizing Borna disease virus (BDV) proteins and a clinical pilot study are presented. Psychiatric patients from a schizophrenia research clinic in Baltimore, Maryland, were examined for antibodies to BDV antigen with traditional indirect immunofluorescence assays (IFA) that used both single and double labeling techniques and also with a Western blot assay capable of detecting antibodies to the three BDV proteins from a human neuroblastoma cell line. Thirteen of 90 (14.4%) patients and 0/20 control subjects had antibodies that recognized more than one BDV protein on the Western blot. Three patients had antibodies that recognized all three BDV proteins. Magnetic resonance imaging assessments of the volume of the putamen (with controls for total cranial volume) differentiated BDV+ from BDV- patients, and there were trend differences for bilateral amygdalae and the left amygdala-hippocampal process. We conclude that: 1. (1) the Western blot assay is superior to IFA assays in BDV serology studies, 2. (2) detection of antibodies to more than one BDV protein is a useful working criterion for seropositivity, 3. (3) the 14.5 kDa BDV protein is 10 times more predictive of seropositivity than either the 38/40 kDa or the 24 kDa protein, 4. (4) there is tentative evidence for a schizophrenia-control difference in the prevalence of anti-BDV antibodies, and 5. (5) it is likely that there are neuroanatomical/behavioral features that differentiate seropositive from seronegative schizophrenic patients.

Original languageEnglish (US)
Pages (from-to)33-44
Number of pages12
JournalPsychiatry Research
Volume56
Issue number1
DOIs
StatePublished - Jan 31 1995
Externally publishedYes

Fingerprint

Borna disease virus
Schizophrenia
Antibodies
Proteins
Western Blotting
Amygdala
Baltimore
Putamen
Virus Diseases
Serology
Indirect Fluorescent Antibody Technique
Neuroblastoma
Fluorescent Antibody Technique
Psychiatry

Keywords

  • Antibodies
  • Immunology
  • Magnetic resonance imaging
  • Putamen

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry
  • Psychology(all)

Cite this

Waltrip, R. W., Buchanan, R. W., Summerfelt, A., Breier, A., Carpenter, W. T., Bryant, N. L., ... Carbone, K. M. (1995). Borna disease virus and schizophrenia. Psychiatry Research, 56(1), 33-44. https://doi.org/10.1016/0165-1781(94)02600-N

Borna disease virus and schizophrenia. / Waltrip, Royce W.; Buchanan, Robert W.; Summerfelt, Ann; Breier, Alan; Carpenter, William T.; Bryant, Nancy L.; Rubin, Steven A.; Carbone, Kathryn M.

In: Psychiatry Research, Vol. 56, No. 1, 31.01.1995, p. 33-44.

Research output: Contribution to journalArticle

Waltrip, RW, Buchanan, RW, Summerfelt, A, Breier, A, Carpenter, WT, Bryant, NL, Rubin, SA & Carbone, KM 1995, 'Borna disease virus and schizophrenia', Psychiatry Research, vol. 56, no. 1, pp. 33-44. https://doi.org/10.1016/0165-1781(94)02600-N
Waltrip RW, Buchanan RW, Summerfelt A, Breier A, Carpenter WT, Bryant NL et al. Borna disease virus and schizophrenia. Psychiatry Research. 1995 Jan 31;56(1):33-44. https://doi.org/10.1016/0165-1781(94)02600-N
Waltrip, Royce W. ; Buchanan, Robert W. ; Summerfelt, Ann ; Breier, Alan ; Carpenter, William T. ; Bryant, Nancy L. ; Rubin, Steven A. ; Carbone, Kathryn M. / Borna disease virus and schizophrenia. In: Psychiatry Research. 1995 ; Vol. 56, No. 1. pp. 33-44.
@article{384d29eef05f4ce0857d4d6642e0b3ae,
title = "Borna disease virus and schizophrenia",
abstract = "The development of a new serological assay method to detect antibodies in human sera recognizing Borna disease virus (BDV) proteins and a clinical pilot study are presented. Psychiatric patients from a schizophrenia research clinic in Baltimore, Maryland, were examined for antibodies to BDV antigen with traditional indirect immunofluorescence assays (IFA) that used both single and double labeling techniques and also with a Western blot assay capable of detecting antibodies to the three BDV proteins from a human neuroblastoma cell line. Thirteen of 90 (14.4{\%}) patients and 0/20 control subjects had antibodies that recognized more than one BDV protein on the Western blot. Three patients had antibodies that recognized all three BDV proteins. Magnetic resonance imaging assessments of the volume of the putamen (with controls for total cranial volume) differentiated BDV+ from BDV- patients, and there were trend differences for bilateral amygdalae and the left amygdala-hippocampal process. We conclude that: 1. (1) the Western blot assay is superior to IFA assays in BDV serology studies, 2. (2) detection of antibodies to more than one BDV protein is a useful working criterion for seropositivity, 3. (3) the 14.5 kDa BDV protein is 10 times more predictive of seropositivity than either the 38/40 kDa or the 24 kDa protein, 4. (4) there is tentative evidence for a schizophrenia-control difference in the prevalence of anti-BDV antibodies, and 5. (5) it is likely that there are neuroanatomical/behavioral features that differentiate seropositive from seronegative schizophrenic patients.",
keywords = "Antibodies, Immunology, Magnetic resonance imaging, Putamen",
author = "Waltrip, {Royce W.} and Buchanan, {Robert W.} and Ann Summerfelt and Alan Breier and Carpenter, {William T.} and Bryant, {Nancy L.} and Rubin, {Steven A.} and Carbone, {Kathryn M.}",
year = "1995",
month = "1",
day = "31",
doi = "10.1016/0165-1781(94)02600-N",
language = "English (US)",
volume = "56",
pages = "33--44",
journal = "Psychiatry Research",
issn = "0165-1781",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Borna disease virus and schizophrenia

AU - Waltrip, Royce W.

AU - Buchanan, Robert W.

AU - Summerfelt, Ann

AU - Breier, Alan

AU - Carpenter, William T.

AU - Bryant, Nancy L.

AU - Rubin, Steven A.

AU - Carbone, Kathryn M.

PY - 1995/1/31

Y1 - 1995/1/31

N2 - The development of a new serological assay method to detect antibodies in human sera recognizing Borna disease virus (BDV) proteins and a clinical pilot study are presented. Psychiatric patients from a schizophrenia research clinic in Baltimore, Maryland, were examined for antibodies to BDV antigen with traditional indirect immunofluorescence assays (IFA) that used both single and double labeling techniques and also with a Western blot assay capable of detecting antibodies to the three BDV proteins from a human neuroblastoma cell line. Thirteen of 90 (14.4%) patients and 0/20 control subjects had antibodies that recognized more than one BDV protein on the Western blot. Three patients had antibodies that recognized all three BDV proteins. Magnetic resonance imaging assessments of the volume of the putamen (with controls for total cranial volume) differentiated BDV+ from BDV- patients, and there were trend differences for bilateral amygdalae and the left amygdala-hippocampal process. We conclude that: 1. (1) the Western blot assay is superior to IFA assays in BDV serology studies, 2. (2) detection of antibodies to more than one BDV protein is a useful working criterion for seropositivity, 3. (3) the 14.5 kDa BDV protein is 10 times more predictive of seropositivity than either the 38/40 kDa or the 24 kDa protein, 4. (4) there is tentative evidence for a schizophrenia-control difference in the prevalence of anti-BDV antibodies, and 5. (5) it is likely that there are neuroanatomical/behavioral features that differentiate seropositive from seronegative schizophrenic patients.

AB - The development of a new serological assay method to detect antibodies in human sera recognizing Borna disease virus (BDV) proteins and a clinical pilot study are presented. Psychiatric patients from a schizophrenia research clinic in Baltimore, Maryland, were examined for antibodies to BDV antigen with traditional indirect immunofluorescence assays (IFA) that used both single and double labeling techniques and also with a Western blot assay capable of detecting antibodies to the three BDV proteins from a human neuroblastoma cell line. Thirteen of 90 (14.4%) patients and 0/20 control subjects had antibodies that recognized more than one BDV protein on the Western blot. Three patients had antibodies that recognized all three BDV proteins. Magnetic resonance imaging assessments of the volume of the putamen (with controls for total cranial volume) differentiated BDV+ from BDV- patients, and there were trend differences for bilateral amygdalae and the left amygdala-hippocampal process. We conclude that: 1. (1) the Western blot assay is superior to IFA assays in BDV serology studies, 2. (2) detection of antibodies to more than one BDV protein is a useful working criterion for seropositivity, 3. (3) the 14.5 kDa BDV protein is 10 times more predictive of seropositivity than either the 38/40 kDa or the 24 kDa protein, 4. (4) there is tentative evidence for a schizophrenia-control difference in the prevalence of anti-BDV antibodies, and 5. (5) it is likely that there are neuroanatomical/behavioral features that differentiate seropositive from seronegative schizophrenic patients.

KW - Antibodies

KW - Immunology

KW - Magnetic resonance imaging

KW - Putamen

UR - http://www.scopus.com/inward/record.url?scp=0028953619&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028953619&partnerID=8YFLogxK

U2 - 10.1016/0165-1781(94)02600-N

DO - 10.1016/0165-1781(94)02600-N

M3 - Article

C2 - 7792340

AN - SCOPUS:0028953619

VL - 56

SP - 33

EP - 44

JO - Psychiatry Research

JF - Psychiatry Research

SN - 0165-1781

IS - 1

ER -